News & Videos - PULMATRIX INC. - Page 3

Pulmatrix Announces $40 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire LEXINGTON, Mass., Feb. 11, 2021 LEXINGTON, Mass. , Feb. 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has entered into definitive agreements with healthcare-focused...

Pulmatrix Reports Third Quarter 2020 Financial Results and Business Updates Focused pipeline with multiple potential clinical and regulatory milestones in 2021 Pulmatrix to receive escalating royalties from partner Sensory Cloud upon sales of FEND, an OTC nasal hygiene product proven to reduce airborne respiratory droplets Completed warrant exercise raising approximately $13.6 million in gross proceeds to advance ongoing programs PR Newswire LEXINGTON, Mass., Nov. 12, 2020 LEXINGTON, Mass. ,...

Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product Proven to Reduce Airborne Respiratory Droplets, with Partner Sensory Cloud Series of Scientific Publications Demonstrate up to 99% Reduction of Airborne Respiratory Droplets Including Those not Captured by Surgical Masks Commercial Launch Provides Immediate, Broad Availability with Pulmatrix to Receive Escalating Royalties on Product Sales PR Newswire LEXINGTON, Mass., Oct. 21, 2020 LEXINGTON, Mass. , Oct. 21, 2020...

Pulmatrix Announces Publication Demonstrating Reduction of Bioaerosols with FEND, an OTC Nasal Hygiene Product Designed to Cleanse Airways of Airborne Particles FEND Administration Lowered Exhaled Particles in Subjects Including Healthy Subjects and a COVID-19 Patient Partner Sensory Cloud to Distribute FEND Worldwide, with Pulmatrix Receiving Escalating Royalties upon Commencement of Sales PR Newswire LEXINGTON, Mass., Sept. 30, 2020 LEXINGTON, Mass. , Sept. 30, 2020 /PRNewswire/ – Pulmatrix,...

Pulmatrix Strengthens Board of Directors with Appointment of Todd Bazemore PR Newswire LEXINGTON, Mass., Sept. 29, 2020 LEXINGTON, Mass. , Sept. 29, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Todd Bazemore , a biopharmaceutical executive with significant experience in...

Pulmatrix Reports Progress on Product Pipeline PR Newswire LEXINGTON, Mass., Sept. 22, 2020 LEXINGTON, Mass. , Sept. 22, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, provides an update on product pipeline. "COVID-19 has presented us with some challenges, but we are positioned to make progress across our product...

Pulmatrix Reports Q2 2020 Results and Business Updates Strategic Partner Sensory Cloud Advancing Toward Commercial Launch of FEND in Fall 2020 as OTC Nasal Hygiene Product for COVID-19 Received MHRA approval of the PUR1800 Pdivb clinical trial, enabling a study start in 2H 2020 Strengthened balance sheet with gross proceeds from a registered direct offering in April and a warrant exercise transaction in July PR Newswire LEXINGTON, Mass., Aug. 7, 2020 LEXINGTON, Mass. , Aug. 7, 2020 /PRNewswire/...

Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles Pulmatrix's Partner Sensory Cloud to Conduct Worldwide Marketing Distribution Pulmatrix to Receive Escalating Royalties upon Commencement of Sales PR Newswire LEXINGTON, Mass., July 8, 2020 LEXINGTON, Mass. , July 8, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing...

Pulmatrix Announces Changes to Board of Directors PR Newswire LEXINGTON, Mass., June 26, 2020 LEXINGTON, Mass. , June 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced upcoming changes to its Board of Directors. Chris Cabell , M.D. is appointed to the Pulmatrix Board of Directors effective June 23, 2020 Steven...

Pulmatrix to Host 2020 Annual Meeting of Stockholders Virtually PR Newswire LEXINGTON, Mass., May 27, 2020 LEXINGTON, Mass. , May 27, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that, due to public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, the location of...

Pulmatrix Reports Q1 2020 Results PR Newswire LEXINGTON, Mass., May 14, 2020 LEXINGTON, Mass. , May 14, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology today reports its Q1 2020 financial results and provides a business update. "We are excited to join the fight against COVID-19 with the announcement of our Sensory...

Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules PR Newswire LEXINGTON, Mass., April 16, 2020 LEXINGTON, Mass. , April 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced that it has entered into definitive agreements with several institutional and...

Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19 PR Newswire LEXINGTON, Mass., April 16, 2020 LEXINGTON, Mass. , April 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced it has entered into a Collaboration and License Agreement with Sensory Cloud, Inc., a...

Pulmatrix Reports 2019 Financial Results and Provides Business Update Initiated Phase 2 study evaluating Pulmazole for the treatment of ABPA Entered licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson* Entered into strategic partnership with Cipla Technologies LLC for the global development and commercialization of Pulmazole PR Newswire LEXINGTON, Mass., March 26, 2020 LEXINGTON, Mass. , March 26, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a...

...

Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA PR Newswire LEXINGTON, Mass., Jan. 30, 2020 LEXINGTON, Mass. , Jan. 30, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PUR1900 ("Pulmazole"), the Company's inhaled itraconazole antifungal candidate being developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma....

Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire LEXINGTON, Mass., Jan. 16, 2020 LEXINGTON, Mass. , Jan. 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The Nasdaq Stock Market LLC, stating that the Company has regained compliance with Nasdaq's minimum $1.00 per share bid price requirement. The letter received noted that for the last 10 consecutive business...

Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies PR Newswire LEXINGTON, Mass., Jan. 6, 2020 LEXINGTON, Mass. , Jan. 6, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that it has entered into a research collaboration with Nocion Therapeutics to explore new technologies to enable and improve...

...

Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors PR Newswire LEXINGTON, Mass., Nov. 4, 2019 LEXINGTON, Mass. , Nov. 4, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced the appointment of Rick Batycky , Ph.D., to its Board of Directors. "Rick brings deep expertise in drug development to the board and we are thrilled to...